Home Rehabilitation After Acute Pulmonary Embolism

September 15, 2026 updated by: Daniel Lachant, University of Rochester

The purpose of this study is to evaluate whether a home rehabilitation program after hospitalization for acute pulmonary embolism (PE) improves clinical outcomes at 3 months compared to usual care. Daily physical activity tasks that incorporate heart rate monitoring will be sent through email or text. This information could help improve the management of acute PE.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • English speaking (>18 years old). Daily messages will be sent in English.
  • Acute PE with right ventricular enlargement or dysfunction defined by echocardiogram report, CT Angiogram report, or elevated cardiac biomarker (NT-pro BNP or troponin).
  • Baseline testing started within 7 days of hospital discharge.

Exclusion Criteria:

  • Pregnancy.
  • Cardiac Effort >2.5 beats/m during 6MWT. This is for safety.
  • Cardiac Effort <1.2 beats/m during 6MWT. They are unlikely to benefit.
  • Resting tachycardia >120 beats/m during screening or at hospital discharge.
  • Suspicion for Chronic Thromboembolic Pulmonary Hypertension.
  • Systolic blood pressure >180 mmHg during screening or at hospital discharge.
  • Inability to walk.
  • Estimated prognosis <12 months at the time of discharge due to underlying co-morbidities.
  • Advanced neurologic disease.
  • Lack of access to email or text messaging.
  • Inability to follow daily instructions.
  • Participation in a structured exercise routine at least three days per week in the prior four weeks.
  • Principal Investigator discretion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Participants who receive daily activity message

The intervention group will receive instructions for a daily activity sent through SMS text message or email.

Participants will receive a text each day with instructions about the daily activity they should complete for that day.

Placebo Comparator: Participants who receive control message

The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day".

Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day."

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mean change in vector magnitude count as measured by actigraphy
Time Frame: 10 weeks

The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the vector magnitude count.

10 weeks
mean change in mean amplitude deviation as measured by actigraphy
Time Frame: 10 weeks

The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the mean amplitude deviation.

10 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mean change in 6 minute walking distance
Time Frame: 12 weeks
12 weeks
mean change in heart rate during a 6 minute walk
Time Frame: 12 weeks
12 weeks
proportion or subjects who develop chronic thromboembolic pulmonary hypertension
Time Frame: 12 weeks
12 weeks
proportion of participants with post-PE syndrome
Time Frame: 12 weeks

Participants will be evaluated by a physician to determine if they have post PE-syndrome

12 weeks
mean change in steps as measured by Actigraph
Time Frame: 12 weeks

The Actigraph triaxial accelerometer will be used to monitor the number of steps taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the step count.

12 weeks
mean change in activity as measured by Actigraph
Time Frame: 12 weeks

The Actigraph triaxial accelerometer will be used to monitor the amount of activity taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the amount of activity.

12 weeks
mean change in quality of life as measured by PROMIS
Time Frame: 12 weeks

The PROMIS questionnaire ranges from 0-99 with higher scores indicating worse outcome.

12 weeks
mean change in quality of life as measured by Emphasis 10
Time Frame: 12 weeks

The Emphasis 10 questionnaire ranges from 0-50 with higher scores indicating worse quality of life.

12 weeks
mean change in quality of life as measured by Pulmonary Embolism quality of life questionnaire
Time Frame: 12 weeks

The pulmonary embolism quality of life questionnaire ranges from 1 to 27 with higher scores indicating worse outcomes.

12 weeks
mean change in oxygen use during a 6 minute walk
Time Frame: 12 weeks

Oxygen use will be measured by a measured by portable K5 metabolic analyzer.

12 weeks
mean change in carbon dioxide production during a 6 minute walk
Time Frame: 12 weeks

Carbon Dioxide use will be measured by a measured by portable K5 metabolic analyzer.

12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Daniel Lachant, DO, University of Rochester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 19, 2022

Primary Completion (Actual)

September 24, 2025

Study Completion (Actual)

September 24, 2025

Study Registration Dates

First Submitted

October 4, 2022

First Submitted That Met QC Criteria

October 4, 2022

First Posted (Actual)

October 7, 2022

Study Record Updates

Last Update Posted (Actual)

September 18, 2026

Last Update Submitted That Met QC Criteria

September 15, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00007680

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.